nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—CYP2C9—Capecitabine—esophageal cancer	0.0989	0.474	CbGbCtD
Gliclazide—ALB—Methotrexate—esophageal cancer	0.06	0.287	CbGbCtD
Gliclazide—CYP2C9—Cisplatin—esophageal cancer	0.0498	0.239	CbGbCtD
Gliclazide—Chlorpropamide—PTGS1—esophageal cancer	0.00203	0.37	CrCbGaD
Gliclazide—Glyburide—ABCC2—esophageal cancer	0.00181	0.33	CrCbGaD
Gliclazide—Thrombophlebitis—Capecitabine—esophageal cancer	0.00141	0.00388	CcSEcCtD
Gliclazide—Sleep disorder—Capecitabine—esophageal cancer	0.00141	0.00388	CcSEcCtD
Gliclazide—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.0014	0.00386	CcSEcCtD
Gliclazide—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00139	0.00384	CcSEcCtD
Gliclazide—Photosensitivity—Capecitabine—esophageal cancer	0.00139	0.00383	CcSEcCtD
Gliclazide—Polyuria—Capecitabine—esophageal cancer	0.00139	0.00383	CcSEcCtD
Gliclazide—Gastroenteritis—Capecitabine—esophageal cancer	0.00138	0.00379	CcSEcCtD
Gliclazide—Abdominal discomfort—Cisplatin—esophageal cancer	0.00137	0.00378	CcSEcCtD
Gliclazide—Deafness—Capecitabine—esophageal cancer	0.00136	0.00376	CcSEcCtD
Gliclazide—Pancytopenia—Cisplatin—esophageal cancer	0.00136	0.00374	CcSEcCtD
Gliclazide—Hepatic failure—Capecitabine—esophageal cancer	0.00136	0.00374	CcSEcCtD
Gliclazide—Haemolytic anaemia—Capecitabine—esophageal cancer	0.00135	0.00372	CcSEcCtD
Gliclazide—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00132	0.00364	CcSEcCtD
Gliclazide—Renal failure acute—Capecitabine—esophageal cancer	0.00132	0.00364	CcSEcCtD
Gliclazide—Increased appetite—Capecitabine—esophageal cancer	0.0013	0.00358	CcSEcCtD
Gliclazide—Thirst—Capecitabine—esophageal cancer	0.00128	0.00353	CcSEcCtD
Gliclazide—Renal impairment—Capecitabine—esophageal cancer	0.00128	0.00353	CcSEcCtD
Gliclazide—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00126	0.00346	CcSEcCtD
Gliclazide—Arthritis—Capecitabine—esophageal cancer	0.00125	0.00346	CcSEcCtD
Gliclazide—Renal failure—Cisplatin—esophageal cancer	0.00125	0.00345	CcSEcCtD
Gliclazide—Vaginal inflammation—Methotrexate—esophageal cancer	0.00125	0.00345	CcSEcCtD
Gliclazide—Myocardial infarction—Cisplatin—esophageal cancer	0.00125	0.00344	CcSEcCtD
Gliclazide—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00125	0.00344	CcSEcCtD
Gliclazide—Cardiac failure—Capecitabine—esophageal cancer	0.00125	0.00344	CcSEcCtD
Gliclazide—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00124	0.00343	CcSEcCtD
Gliclazide—Conjunctivitis—Cisplatin—esophageal cancer	0.00124	0.00341	CcSEcCtD
Gliclazide—Hyponatraemia—Capecitabine—esophageal cancer	0.00122	0.00337	CcSEcCtD
Gliclazide—Melaena—Methotrexate—esophageal cancer	0.00122	0.00337	CcSEcCtD
Gliclazide—Cystitis noninfective—Methotrexate—esophageal cancer	0.00122	0.00337	CcSEcCtD
Gliclazide—Pain in extremity—Capecitabine—esophageal cancer	0.00122	0.00336	CcSEcCtD
Gliclazide—Osteoarthritis—Capecitabine—esophageal cancer	0.00122	0.00336	CcSEcCtD
Gliclazide—Diplopia—Capecitabine—esophageal cancer	0.00122	0.00336	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00122	0.00336	CcSEcCtD
Gliclazide—Cystitis—Methotrexate—esophageal cancer	0.00121	0.00333	CcSEcCtD
Gliclazide—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00121	0.00332	CcSEcCtD
Gliclazide—Vaginal infection—Methotrexate—esophageal cancer	0.00118	0.00325	CcSEcCtD
Gliclazide—Bradycardia—Cisplatin—esophageal cancer	0.00116	0.00321	CcSEcCtD
Gliclazide—Coma—Methotrexate—esophageal cancer	0.00114	0.00315	CcSEcCtD
Gliclazide—Urine output increased—Methotrexate—esophageal cancer	0.00113	0.00311	CcSEcCtD
Gliclazide—Neoplasm—Methotrexate—esophageal cancer	0.00113	0.00311	CcSEcCtD
Gliclazide—Bladder pain—Methotrexate—esophageal cancer	0.00113	0.00311	CcSEcCtD
Gliclazide—Dry skin—Capecitabine—esophageal cancer	0.00112	0.00308	CcSEcCtD
Gliclazide—Visual impairment—Cisplatin—esophageal cancer	0.0011	0.00304	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.0011	0.00303	CcSEcCtD
Gliclazide—Gastritis—Capecitabine—esophageal cancer	0.00108	0.00297	CcSEcCtD
Gliclazide—Eye disorder—Cisplatin—esophageal cancer	0.00107	0.00295	CcSEcCtD
Gliclazide—Tinnitus—Cisplatin—esophageal cancer	0.00107	0.00294	CcSEcCtD
Gliclazide—Flushing—Cisplatin—esophageal cancer	0.00106	0.00293	CcSEcCtD
Gliclazide—Abdominal distension—Capecitabine—esophageal cancer	0.00106	0.00292	CcSEcCtD
Gliclazide—Asthma—Capecitabine—esophageal cancer	0.00105	0.0029	CcSEcCtD
Gliclazide—Thrombophlebitis—Methotrexate—esophageal cancer	0.00105	0.00289	CcSEcCtD
Gliclazide—Photosensitivity—Methotrexate—esophageal cancer	0.00103	0.00285	CcSEcCtD
Gliclazide—Polyuria—Methotrexate—esophageal cancer	0.00103	0.00285	CcSEcCtD
Gliclazide—Angina pectoris—Capecitabine—esophageal cancer	0.00103	0.00283	CcSEcCtD
Gliclazide—Arrhythmia—Cisplatin—esophageal cancer	0.00102	0.00282	CcSEcCtD
Gliclazide—Bronchitis—Capecitabine—esophageal cancer	0.00101	0.00279	CcSEcCtD
Gliclazide—Abdominal discomfort—Capecitabine—esophageal cancer	0.00101	0.00278	CcSEcCtD
Gliclazide—Hepatic failure—Methotrexate—esophageal cancer	0.00101	0.00278	CcSEcCtD
Gliclazide—Pancytopenia—Capecitabine—esophageal cancer	0.001	0.00276	CcSEcCtD
Gliclazide—Malnutrition—Cisplatin—esophageal cancer	0.000996	0.00274	CcSEcCtD
Gliclazide—Erythema—Cisplatin—esophageal cancer	0.000996	0.00274	CcSEcCtD
Gliclazide—Chlorpropamide—ABCB1—esophageal cancer	0.000986	0.18	CrCbGaD
Gliclazide—Renal failure acute—Methotrexate—esophageal cancer	0.000983	0.00271	CcSEcCtD
Gliclazide—Flatulence—Cisplatin—esophageal cancer	0.000981	0.0027	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000979	0.0027	CcSEcCtD
Gliclazide—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000962	0.00265	CcSEcCtD
Gliclazide—Weight increased—Capecitabine—esophageal cancer	0.000959	0.00264	CcSEcCtD
Gliclazide—Visual disturbance—Methotrexate—esophageal cancer	0.000957	0.00264	CcSEcCtD
Gliclazide—Hyperglycaemia—Capecitabine—esophageal cancer	0.00095	0.00262	CcSEcCtD
Gliclazide—Pneumonia—Capecitabine—esophageal cancer	0.000945	0.0026	CcSEcCtD
Gliclazide—Depression—Capecitabine—esophageal cancer	0.000937	0.00258	CcSEcCtD
Gliclazide—Tremor—Cisplatin—esophageal cancer	0.000933	0.00257	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000931	0.00257	CcSEcCtD
Gliclazide—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000926	0.00255	CcSEcCtD
Gliclazide—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000926	0.00255	CcSEcCtD
Gliclazide—Ill-defined disorder—Cisplatin—esophageal cancer	0.000924	0.00255	CcSEcCtD
Gliclazide—Renal failure—Capecitabine—esophageal cancer	0.000923	0.00254	CcSEcCtD
Gliclazide—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000921	0.00254	CcSEcCtD
Gliclazide—Myocardial infarction—Capecitabine—esophageal cancer	0.000921	0.00254	CcSEcCtD
Gliclazide—Anaemia—Cisplatin—esophageal cancer	0.00092	0.00254	CcSEcCtD
Gliclazide—Jaundice—Capecitabine—esophageal cancer	0.000916	0.00252	CcSEcCtD
Gliclazide—Urinary tract infection—Capecitabine—esophageal cancer	0.000913	0.00252	CcSEcCtD
Gliclazide—Conjunctivitis—Capecitabine—esophageal cancer	0.000913	0.00252	CcSEcCtD
Gliclazide—Osteoarthritis—Methotrexate—esophageal cancer	0.000907	0.0025	CcSEcCtD
Gliclazide—Malaise—Cisplatin—esophageal cancer	0.000898	0.00248	CcSEcCtD
Gliclazide—Leukopenia—Cisplatin—esophageal cancer	0.000891	0.00246	CcSEcCtD
Gliclazide—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000888	0.00245	CcSEcCtD
Gliclazide—Epistaxis—Capecitabine—esophageal cancer	0.000886	0.00244	CcSEcCtD
Gliclazide—Agranulocytosis—Capecitabine—esophageal cancer	0.000877	0.00242	CcSEcCtD
Gliclazide—Convulsion—Cisplatin—esophageal cancer	0.000863	0.00238	CcSEcCtD
Gliclazide—Bradycardia—Capecitabine—esophageal cancer	0.000858	0.00237	CcSEcCtD
Gliclazide—Myalgia—Cisplatin—esophageal cancer	0.000848	0.00234	CcSEcCtD
Gliclazide—Rhinitis—Capecitabine—esophageal cancer	0.000845	0.00233	CcSEcCtD
Gliclazide—Anxiety—Cisplatin—esophageal cancer	0.000845	0.00233	CcSEcCtD
Gliclazide—Hepatitis—Capecitabine—esophageal cancer	0.000843	0.00232	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000842	0.00232	CcSEcCtD
Gliclazide—Hypoaesthesia—Capecitabine—esophageal cancer	0.000839	0.00231	CcSEcCtD
Gliclazide—Discomfort—Cisplatin—esophageal cancer	0.000838	0.00231	CcSEcCtD
Gliclazide—Pharyngitis—Capecitabine—esophageal cancer	0.000837	0.00231	CcSEcCtD
Gliclazide—Oedema peripheral—Capecitabine—esophageal cancer	0.000831	0.00229	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000817	0.00225	CcSEcCtD
Gliclazide—Visual impairment—Capecitabine—esophageal cancer	0.000813	0.00224	CcSEcCtD
Gliclazide—Infection—Cisplatin—esophageal cancer	0.000807	0.00223	CcSEcCtD
Gliclazide—Erythema multiforme—Capecitabine—esophageal cancer	0.000797	0.0022	CcSEcCtD
Gliclazide—Nervous system disorder—Cisplatin—esophageal cancer	0.000797	0.0022	CcSEcCtD
Gliclazide—Thrombocytopenia—Cisplatin—esophageal cancer	0.000796	0.00219	CcSEcCtD
Gliclazide—Tachycardia—Cisplatin—esophageal cancer	0.000793	0.00219	CcSEcCtD
Gliclazide—Skin disorder—Cisplatin—esophageal cancer	0.000789	0.00218	CcSEcCtD
Gliclazide—Eye disorder—Capecitabine—esophageal cancer	0.000788	0.00217	CcSEcCtD
Gliclazide—Tinnitus—Capecitabine—esophageal cancer	0.000786	0.00217	CcSEcCtD
Gliclazide—Hyperhidrosis—Cisplatin—esophageal cancer	0.000786	0.00217	CcSEcCtD
Gliclazide—Asthma—Methotrexate—esophageal cancer	0.000784	0.00216	CcSEcCtD
Gliclazide—Flushing—Capecitabine—esophageal cancer	0.000783	0.00216	CcSEcCtD
Gliclazide—Hypotension—Cisplatin—esophageal cancer	0.000759	0.00209	CcSEcCtD
Gliclazide—Chills—Capecitabine—esophageal cancer	0.000757	0.00209	CcSEcCtD
Gliclazide—Arrhythmia—Capecitabine—esophageal cancer	0.000753	0.00208	CcSEcCtD
Gliclazide—Abdominal discomfort—Methotrexate—esophageal cancer	0.000752	0.00207	CcSEcCtD
Gliclazide—Pancytopenia—Methotrexate—esophageal cancer	0.000745	0.00205	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00074	0.00204	CcSEcCtD
Gliclazide—Mental disorder—Capecitabine—esophageal cancer	0.000739	0.00204	CcSEcCtD
Gliclazide—Malnutrition—Capecitabine—esophageal cancer	0.000734	0.00202	CcSEcCtD
Gliclazide—Erythema—Capecitabine—esophageal cancer	0.000734	0.00202	CcSEcCtD
Gliclazide—Paraesthesia—Cisplatin—esophageal cancer	0.00073	0.00201	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000729	0.00201	CcSEcCtD
Gliclazide—Dyspnoea—Cisplatin—esophageal cancer	0.000725	0.002	CcSEcCtD
Gliclazide—Flatulence—Capecitabine—esophageal cancer	0.000723	0.00199	CcSEcCtD
Gliclazide—Erectile dysfunction—Methotrexate—esophageal cancer	0.000722	0.00199	CcSEcCtD
Gliclazide—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000716	0.00197	CcSEcCtD
Gliclazide—Back pain—Capecitabine—esophageal cancer	0.00071	0.00196	CcSEcCtD
Gliclazide—Pneumonia—Methotrexate—esophageal cancer	0.000703	0.00194	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000702	0.00193	CcSEcCtD
Gliclazide—Drowsiness—Methotrexate—esophageal cancer	0.000699	0.00193	CcSEcCtD
Gliclazide—Depression—Methotrexate—esophageal cancer	0.000697	0.00192	CcSEcCtD
Gliclazide—Pain—Cisplatin—esophageal cancer	0.000695	0.00192	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000693	0.00191	CcSEcCtD
Gliclazide—Tremor—Capecitabine—esophageal cancer	0.000688	0.0019	CcSEcCtD
Gliclazide—Renal failure—Methotrexate—esophageal cancer	0.000687	0.00189	CcSEcCtD
Gliclazide—Ill-defined disorder—Capecitabine—esophageal cancer	0.000681	0.00188	CcSEcCtD
Gliclazide—Conjunctivitis—Methotrexate—esophageal cancer	0.00068	0.00187	CcSEcCtD
Gliclazide—Anaemia—Capecitabine—esophageal cancer	0.000678	0.00187	CcSEcCtD
Gliclazide—Sweating—Methotrexate—esophageal cancer	0.00067	0.00185	CcSEcCtD
Gliclazide—Feeling abnormal—Cisplatin—esophageal cancer	0.00067	0.00185	CcSEcCtD
Gliclazide—Glyburide—ABCB1—esophageal cancer	0.000666	0.121	CrCbGaD
Gliclazide—Malaise—Capecitabine—esophageal cancer	0.000662	0.00182	CcSEcCtD
Gliclazide—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000661	0.00182	CcSEcCtD
Gliclazide—Epistaxis—Methotrexate—esophageal cancer	0.000659	0.00182	CcSEcCtD
Gliclazide—Leukopenia—Capecitabine—esophageal cancer	0.000657	0.00181	CcSEcCtD
Gliclazide—Agranulocytosis—Methotrexate—esophageal cancer	0.000652	0.0018	CcSEcCtD
Gliclazide—Palpitations—Capecitabine—esophageal cancer	0.000649	0.00179	CcSEcCtD
Gliclazide—Loss of consciousness—Capecitabine—esophageal cancer	0.000645	0.00178	CcSEcCtD
Gliclazide—Body temperature increased—Cisplatin—esophageal cancer	0.000642	0.00177	CcSEcCtD
Gliclazide—Cough—Capecitabine—esophageal cancer	0.00064	0.00177	CcSEcCtD
Gliclazide—Hypertension—Capecitabine—esophageal cancer	0.000634	0.00175	CcSEcCtD
Gliclazide—Hepatitis—Methotrexate—esophageal cancer	0.000628	0.00173	CcSEcCtD
Gliclazide—Chest pain—Capecitabine—esophageal cancer	0.000625	0.00172	CcSEcCtD
Gliclazide—Arthralgia—Capecitabine—esophageal cancer	0.000625	0.00172	CcSEcCtD
Gliclazide—Myalgia—Capecitabine—esophageal cancer	0.000625	0.00172	CcSEcCtD
Gliclazide—Pharyngitis—Methotrexate—esophageal cancer	0.000623	0.00172	CcSEcCtD
Gliclazide—Anxiety—Capecitabine—esophageal cancer	0.000623	0.00172	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000621	0.00171	CcSEcCtD
Gliclazide—Discomfort—Capecitabine—esophageal cancer	0.000617	0.0017	CcSEcCtD
Gliclazide—Dry mouth—Capecitabine—esophageal cancer	0.000611	0.00168	CcSEcCtD
Gliclazide—Visual impairment—Methotrexate—esophageal cancer	0.000605	0.00167	CcSEcCtD
Gliclazide—Confusional state—Capecitabine—esophageal cancer	0.000604	0.00166	CcSEcCtD
Gliclazide—Hypersensitivity—Cisplatin—esophageal cancer	0.000599	0.00165	CcSEcCtD
Gliclazide—Infection—Capecitabine—esophageal cancer	0.000595	0.00164	CcSEcCtD
Gliclazide—Erythema multiforme—Methotrexate—esophageal cancer	0.000593	0.00164	CcSEcCtD
Gliclazide—Nervous system disorder—Capecitabine—esophageal cancer	0.000587	0.00162	CcSEcCtD
Gliclazide—Eye disorder—Methotrexate—esophageal cancer	0.000587	0.00162	CcSEcCtD
Gliclazide—Thrombocytopenia—Capecitabine—esophageal cancer	0.000587	0.00162	CcSEcCtD
Gliclazide—Tinnitus—Methotrexate—esophageal cancer	0.000585	0.00161	CcSEcCtD
Gliclazide—Tachycardia—Capecitabine—esophageal cancer	0.000585	0.00161	CcSEcCtD
Gliclazide—Asthenia—Cisplatin—esophageal cancer	0.000583	0.00161	CcSEcCtD
Gliclazide—Skin disorder—Capecitabine—esophageal cancer	0.000582	0.0016	CcSEcCtD
Gliclazide—Hyperhidrosis—Capecitabine—esophageal cancer	0.000579	0.0016	CcSEcCtD
Gliclazide—Chills—Methotrexate—esophageal cancer	0.000563	0.00155	CcSEcCtD
Gliclazide—Hypotension—Capecitabine—esophageal cancer	0.00056	0.00154	CcSEcCtD
Gliclazide—Diarrhoea—Cisplatin—esophageal cancer	0.000556	0.00153	CcSEcCtD
Gliclazide—Mental disorder—Methotrexate—esophageal cancer	0.00055	0.00152	CcSEcCtD
Gliclazide—Malnutrition—Methotrexate—esophageal cancer	0.000546	0.00151	CcSEcCtD
Gliclazide—Erythema—Methotrexate—esophageal cancer	0.000546	0.00151	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000546	0.0015	CcSEcCtD
Gliclazide—Insomnia—Capecitabine—esophageal cancer	0.000542	0.00149	CcSEcCtD
Gliclazide—Paraesthesia—Capecitabine—esophageal cancer	0.000538	0.00148	CcSEcCtD
Gliclazide—Dyspnoea—Capecitabine—esophageal cancer	0.000534	0.00147	CcSEcCtD
Gliclazide—Back pain—Methotrexate—esophageal cancer	0.000529	0.00146	CcSEcCtD
Gliclazide—Dyspepsia—Capecitabine—esophageal cancer	0.000527	0.00145	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000517	0.00143	CcSEcCtD
Gliclazide—Vomiting—Cisplatin—esophageal cancer	0.000517	0.00142	CcSEcCtD
Gliclazide—Fatigue—Capecitabine—esophageal cancer	0.000516	0.00142	CcSEcCtD
Gliclazide—Rash—Cisplatin—esophageal cancer	0.000512	0.00141	CcSEcCtD
Gliclazide—Pain—Capecitabine—esophageal cancer	0.000512	0.00141	CcSEcCtD
Gliclazide—Constipation—Capecitabine—esophageal cancer	0.000512	0.00141	CcSEcCtD
Gliclazide—Dermatitis—Cisplatin—esophageal cancer	0.000512	0.00141	CcSEcCtD
Gliclazide—Ill-defined disorder—Methotrexate—esophageal cancer	0.000507	0.0014	CcSEcCtD
Gliclazide—Anaemia—Methotrexate—esophageal cancer	0.000505	0.00139	CcSEcCtD
Gliclazide—Feeling abnormal—Capecitabine—esophageal cancer	0.000494	0.00136	CcSEcCtD
Gliclazide—Malaise—Methotrexate—esophageal cancer	0.000493	0.00136	CcSEcCtD
Gliclazide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00049	0.00135	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—esophageal cancer	0.000489	0.00135	CcSEcCtD
Gliclazide—Nausea—Cisplatin—esophageal cancer	0.000483	0.00133	CcSEcCtD
Gliclazide—Cough—Methotrexate—esophageal cancer	0.000477	0.00131	CcSEcCtD
Gliclazide—Urticaria—Capecitabine—esophageal cancer	0.000476	0.00131	CcSEcCtD
Gliclazide—Abdominal pain—Capecitabine—esophageal cancer	0.000474	0.00131	CcSEcCtD
Gliclazide—Body temperature increased—Capecitabine—esophageal cancer	0.000474	0.00131	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—esophageal cancer	0.000473	0.0013	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—esophageal cancer	0.000465	0.00128	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—esophageal cancer	0.000465	0.00128	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—esophageal cancer	0.000465	0.00128	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000462	0.00127	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—esophageal cancer	0.00046	0.00127	CcSEcCtD
Gliclazide—Confusional state—Methotrexate—esophageal cancer	0.00045	0.00124	CcSEcCtD
Gliclazide—Infection—Methotrexate—esophageal cancer	0.000443	0.00122	CcSEcCtD
Gliclazide—Hypersensitivity—Capecitabine—esophageal cancer	0.000441	0.00122	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—esophageal cancer	0.000437	0.00121	CcSEcCtD
Gliclazide—Thrombocytopenia—Methotrexate—esophageal cancer	0.000437	0.0012	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—esophageal cancer	0.000433	0.00119	CcSEcCtD
Gliclazide—Hyperhidrosis—Methotrexate—esophageal cancer	0.000431	0.00119	CcSEcCtD
Gliclazide—Asthenia—Capecitabine—esophageal cancer	0.00043	0.00118	CcSEcCtD
Gliclazide—Pruritus—Capecitabine—esophageal cancer	0.000424	0.00117	CcSEcCtD
Gliclazide—Hypotension—Methotrexate—esophageal cancer	0.000417	0.00115	CcSEcCtD
Gliclazide—Diarrhoea—Capecitabine—esophageal cancer	0.00041	0.00113	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000406	0.00112	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—esophageal cancer	0.000403	0.00111	CcSEcCtD
Gliclazide—Paraesthesia—Methotrexate—esophageal cancer	0.0004	0.0011	CcSEcCtD
Gliclazide—Dyspnoea—Methotrexate—esophageal cancer	0.000398	0.0011	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—esophageal cancer	0.000396	0.00109	CcSEcCtD
Gliclazide—Dizziness—Capecitabine—esophageal cancer	0.000396	0.00109	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—esophageal cancer	0.000393	0.00108	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000385	0.00106	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—esophageal cancer	0.000384	0.00106	CcSEcCtD
Gliclazide—Pain—Methotrexate—esophageal cancer	0.000381	0.00105	CcSEcCtD
Gliclazide—Vomiting—Capecitabine—esophageal cancer	0.000381	0.00105	CcSEcCtD
Gliclazide—Rash—Capecitabine—esophageal cancer	0.000378	0.00104	CcSEcCtD
Gliclazide—Dermatitis—Capecitabine—esophageal cancer	0.000377	0.00104	CcSEcCtD
Gliclazide—Headache—Capecitabine—esophageal cancer	0.000375	0.00103	CcSEcCtD
Gliclazide—Feeling abnormal—Methotrexate—esophageal cancer	0.000367	0.00101	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000365	0.00101	CcSEcCtD
Gliclazide—Nausea—Capecitabine—esophageal cancer	0.000356	0.000981	CcSEcCtD
Gliclazide—Urticaria—Methotrexate—esophageal cancer	0.000354	0.000976	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—esophageal cancer	0.000353	0.000972	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—esophageal cancer	0.000353	0.000972	CcSEcCtD
Gliclazide—Hypersensitivity—Methotrexate—esophageal cancer	0.000329	0.000906	CcSEcCtD
Gliclazide—Asthenia—Methotrexate—esophageal cancer	0.00032	0.000882	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—esophageal cancer	0.000315	0.00087	CcSEcCtD
Gliclazide—Diarrhoea—Methotrexate—esophageal cancer	0.000305	0.000841	CcSEcCtD
Gliclazide—Dizziness—Methotrexate—esophageal cancer	0.000295	0.000813	CcSEcCtD
Gliclazide—Vomiting—Methotrexate—esophageal cancer	0.000284	0.000782	CcSEcCtD
Gliclazide—Rash—Methotrexate—esophageal cancer	0.000281	0.000775	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—esophageal cancer	0.000281	0.000774	CcSEcCtD
Gliclazide—Headache—Methotrexate—esophageal cancer	0.000279	0.00077	CcSEcCtD
Gliclazide—Nausea—Methotrexate—esophageal cancer	0.000265	0.00073	CcSEcCtD
Gliclazide—ABCC8—Metabolism—ALDOB—esophageal cancer	0.000219	0.000518	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000218	0.000515	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000218	0.000515	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000215	0.000508	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CSNK1A1—esophageal cancer	0.000213	0.000503	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALDOB—esophageal cancer	0.000213	0.000503	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—CDKN1A—esophageal cancer	0.000211	0.000499	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GAPDH—esophageal cancer	0.000211	0.000499	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.00021	0.000497	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—ERBB2—esophageal cancer	0.00021	0.000495	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CRABP1—esophageal cancer	0.000209	0.000494	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KDR—esophageal cancer	0.000209	0.000494	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000208	0.000491	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PFN1—esophageal cancer	0.000207	0.00049	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—PTGS2—esophageal cancer	0.000205	0.000485	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000205	0.000485	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MET—esophageal cancer	0.000205	0.000484	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GAPDH—esophageal cancer	0.000205	0.000484	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CRABP1—esophageal cancer	0.000203	0.000479	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000202	0.000478	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—EP300—esophageal cancer	0.000201	0.000475	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000199	0.000471	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000199	0.000471	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PFN1—esophageal cancer	0.000199	0.00047	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GNG7—esophageal cancer	0.000199	0.00047	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—NOTCH1—esophageal cancer	0.000197	0.000466	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—NOS2—esophageal cancer	0.000195	0.000461	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—PIK3CA—esophageal cancer	0.000193	0.000457	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GNG7—esophageal cancer	0.000193	0.000456	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.000192	0.000455	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALDH2—esophageal cancer	0.000186	0.000441	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.000186	0.00044	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALDH2—esophageal cancer	0.000181	0.000427	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ELMO1—esophageal cancer	0.000179	0.000422	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CREBBP—esophageal cancer	0.000179	0.000422	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTT1—esophageal cancer	0.000177	0.000419	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP2A6—esophageal cancer	0.000175	0.000414	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—CREBBP—esophageal cancer	0.000175	0.000414	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKAP13—esophageal cancer	0.000175	0.000413	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000174	0.00041	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTT1—esophageal cancer	0.000172	0.000406	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000171	0.000405	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP2A6—esophageal cancer	0.00017	0.000402	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CFL1—esophageal cancer	0.000168	0.000397	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ENO1—esophageal cancer	0.000166	0.000393	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS1—esophageal cancer	0.000166	0.000393	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000166	0.000392	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PSME1—esophageal cancer	0.000164	0.000387	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PSME2—esophageal cancer	0.000164	0.000387	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000161	0.000381	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS1—esophageal cancer	0.000161	0.000381	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ENO1—esophageal cancer	0.000161	0.000381	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PDE4D—esophageal cancer	0.00016	0.000378	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PSME2—esophageal cancer	0.000159	0.000375	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PSME1—esophageal cancer	0.000159	0.000375	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—GNG7—esophageal cancer	0.000158	0.000374	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—NOS3—esophageal cancer	0.000157	0.000371	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000156	0.000368	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TP53—esophageal cancer	0.000154	0.000363	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GNG7—esophageal cancer	0.000152	0.000359	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000151	0.000358	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000151	0.000357	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—ERBB2—esophageal cancer	0.00015	0.000354	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—EGFR—esophageal cancer	0.000145	0.000343	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—esophageal cancer	0.000144	0.00034	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—XIAP—esophageal cancer	0.000142	0.000337	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000142	0.000336	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP1B1—esophageal cancer	0.000141	0.000334	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP1B1—esophageal cancer	0.000137	0.000324	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000137	0.000324	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000136	0.000321	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CTNNA1—esophageal cancer	0.000135	0.000318	CbGpPWpGaD
Gliclazide—ALB—Metabolism—BLVRB—esophageal cancer	0.000135	0.000318	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC52A3—esophageal cancer	0.000135	0.000318	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL2—esophageal cancer	0.000134	0.000316	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP19A1—esophageal cancer	0.000133	0.000314	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HSPA5—esophageal cancer	0.000129	0.000305	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP19A1—esophageal cancer	0.000129	0.000304	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PSME2—esophageal cancer	0.000125	0.000296	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PSME1—esophageal cancer	0.000125	0.000296	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ANXA1—esophageal cancer	0.000124	0.000294	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000124	0.000293	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EP300—esophageal cancer	0.000122	0.000288	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—HMOX1—esophageal cancer	0.000121	0.000287	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SST—esophageal cancer	0.000121	0.000286	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC52A3—esophageal cancer	0.000121	0.000286	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—BLVRB—esophageal cancer	0.000121	0.000286	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.00012	0.000284	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—EP300—esophageal cancer	0.000119	0.000282	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GHRL—esophageal cancer	0.000118	0.000279	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOTCH3—esophageal cancer	0.000118	0.000279	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—HMOX1—esophageal cancer	0.000118	0.000278	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ABCB1—esophageal cancer	0.000116	0.000275	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FBXW7—esophageal cancer	0.000116	0.000274	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC10A2—esophageal cancer	0.000114	0.00027	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CA1—esophageal cancer	0.000114	0.00027	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ABCB1—esophageal cancer	0.000113	0.000267	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.00011	0.00026	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.00011	0.00026	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000108	0.000255	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOTCH2—esophageal cancer	0.000106	0.00025	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CA2—esophageal cancer	0.000105	0.000247	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EGFR—esophageal cancer	0.000104	0.000245	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC10A2—esophageal cancer	0.000103	0.000243	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CA1—esophageal cancer	0.000103	0.000243	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000102	0.000242	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	9.85e-05	0.000233	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLCE1—esophageal cancer	9.73e-05	0.00023	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ADH7—esophageal cancer	9.73e-05	0.00023	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	9.62e-05	0.000227	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ABL1—esophageal cancer	9.55e-05	0.000226	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CA2—esophageal cancer	9.39e-05	0.000222	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFBR2—esophageal cancer	9.39e-05	0.000222	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC10A2—esophageal cancer	9.37e-05	0.000221	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CA1—esophageal cancer	9.37e-05	0.000221	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	9.18e-05	0.000217	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SMAD4—esophageal cancer	8.89e-05	0.00021	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CA—esophageal cancer	8.83e-05	0.000209	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ADH7—esophageal cancer	8.73e-05	0.000206	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLCE1—esophageal cancer	8.73e-05	0.000206	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	8.63e-05	0.000204	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CA2—esophageal cancer	8.57e-05	0.000202	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—esophageal cancer	8.54e-05	0.000202	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ADH1B—esophageal cancer	8.53e-05	0.000202	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	8.37e-05	0.000198	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—HMOX1—esophageal cancer	8.34e-05	0.000197	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMP—esophageal cancer	8.15e-05	0.000193	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ABCB1—esophageal cancer	8.01e-05	0.000189	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLCE1—esophageal cancer	7.96e-05	0.000188	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ADH7—esophageal cancer	7.96e-05	0.000188	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP26A1—esophageal cancer	7.93e-05	0.000187	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	7.87e-05	0.000186	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CREBBP—esophageal cancer	7.78e-05	0.000184	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALOX15—esophageal cancer	7.73e-05	0.000183	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ADH1B—esophageal cancer	7.66e-05	0.000181	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CREBBP—esophageal cancer	7.54e-05	0.000178	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TPI1—esophageal cancer	7.37e-05	0.000174	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTO1—esophageal cancer	7.37e-05	0.000174	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMP—esophageal cancer	7.32e-05	0.000173	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HIF1A—esophageal cancer	7.27e-05	0.000172	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP26A1—esophageal cancer	7.12e-05	0.000168	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALDOB—esophageal cancer	7.07e-05	0.000167	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ADH1B—esophageal cancer	6.98e-05	0.000165	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NOS3—esophageal cancer	6.96e-05	0.000165	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KDR—esophageal cancer	6.96e-05	0.000164	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALOX15—esophageal cancer	6.94e-05	0.000164	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS2—esophageal cancer	6.89e-05	0.000163	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GAPDH—esophageal cancer	6.8e-05	0.000161	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NOS3—esophageal cancer	6.75e-05	0.00016	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CRABP1—esophageal cancer	6.74e-05	0.000159	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMP—esophageal cancer	6.67e-05	0.000158	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TPI1—esophageal cancer	6.62e-05	0.000156	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTO1—esophageal cancer	6.62e-05	0.000156	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOTCH1—esophageal cancer	6.55e-05	0.000155	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP26A1—esophageal cancer	6.49e-05	0.000153	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GNG7—esophageal cancer	6.41e-05	0.000152	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—esophageal cancer	6.37e-05	0.000151	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALDOB—esophageal cancer	6.35e-05	0.00015	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALOX15—esophageal cancer	6.33e-05	0.00015	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CREBBP—esophageal cancer	6.18e-05	0.000146	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—esophageal cancer	6.17e-05	0.000146	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GAPDH—esophageal cancer	6.11e-05	0.000144	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CRABP1—esophageal cancer	6.05e-05	0.000143	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	6.04e-05	0.000143	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTO1—esophageal cancer	6.04e-05	0.000143	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TPI1—esophageal cancer	6.04e-05	0.000143	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALDH2—esophageal cancer	6.01e-05	0.000142	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CREBBP—esophageal cancer	5.94e-05	0.00014	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALDOB—esophageal cancer	5.79e-05	0.000137	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GNG7—esophageal cancer	5.76e-05	0.000136	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTT1—esophageal cancer	5.72e-05	0.000135	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP2A6—esophageal cancer	5.65e-05	0.000134	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.63e-05	0.000133	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GAPDH—esophageal cancer	5.57e-05	0.000132	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS3—esophageal cancer	5.54e-05	0.000131	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CRABP1—esophageal cancer	5.52e-05	0.00013	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALDH2—esophageal cancer	5.4e-05	0.000128	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ENO1—esophageal cancer	5.36e-05	0.000127	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS1—esophageal cancer	5.36e-05	0.000127	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	5.35e-05	0.000127	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOS3—esophageal cancer	5.32e-05	0.000126	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—EP300—esophageal cancer	5.3e-05	0.000125	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PSME2—esophageal cancer	5.28e-05	0.000125	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PSME1—esophageal cancer	5.28e-05	0.000125	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GNG7—esophageal cancer	5.25e-05	0.000124	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—EP300—esophageal cancer	5.14e-05	0.000121	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTT1—esophageal cancer	5.13e-05	0.000121	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP2A6—esophageal cancer	5.07e-05	0.00012	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.05e-05	0.000119	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB2—esophageal cancer	4.97e-05	0.000118	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALDH2—esophageal cancer	4.92e-05	0.000116	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS1—esophageal cancer	4.81e-05	0.000114	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ENO1—esophageal cancer	4.81e-05	0.000114	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PSME1—esophageal cancer	4.74e-05	0.000112	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PSME2—esophageal cancer	4.74e-05	0.000112	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTT1—esophageal cancer	4.68e-05	0.000111	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2A6—esophageal cancer	4.63e-05	0.000109	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.61e-05	0.000109	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	4.61e-05	0.000109	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP1B1—esophageal cancer	4.56e-05	0.000108	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—esophageal cancer	4.4e-05	0.000104	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ENO1—esophageal cancer	4.39e-05	0.000104	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS1—esophageal cancer	4.39e-05	0.000104	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PSME2—esophageal cancer	4.32e-05	0.000102	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PSME1—esophageal cancer	4.32e-05	0.000102	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP19A1—esophageal cancer	4.28e-05	0.000101	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1A—esophageal cancer	4.25e-05	0.0001	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EP300—esophageal cancer	4.21e-05	9.95e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.14e-05	9.78e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP1B1—esophageal cancer	4.09e-05	9.67e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EP300—esophageal cancer	4.05e-05	9.56e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—esophageal cancer	3.92e-05	9.26e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HMOX1—esophageal cancer	3.91e-05	9.24e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP19A1—esophageal cancer	3.84e-05	9.09e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.83e-05	9.06e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—esophageal cancer	3.8e-05	8.98e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.77e-05	8.92e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCB1—esophageal cancer	3.75e-05	8.87e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP1B1—esophageal cancer	3.73e-05	8.81e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—esophageal cancer	3.53e-05	8.33e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HMOX1—esophageal cancer	3.51e-05	8.29e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP19A1—esophageal cancer	3.51e-05	8.29e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—esophageal cancer	3.45e-05	8.15e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.44e-05	8.14e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCB1—esophageal cancer	3.37e-05	7.96e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HMOX1—esophageal cancer	3.2e-05	7.56e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.14e-05	7.42e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—esophageal cancer	3.12e-05	7.36e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCB1—esophageal cancer	3.07e-05	7.26e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—esophageal cancer	3.01e-05	7.12e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—esophageal cancer	2.99e-05	7.07e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—esophageal cancer	2.9e-05	6.84e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.84e-05	6.7e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.55e-05	6.02e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CREBBP—esophageal cancer	2.51e-05	5.93e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.32e-05	5.49e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CREBBP—esophageal cancer	2.25e-05	5.32e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NOS3—esophageal cancer	2.24e-05	5.31e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—esophageal cancer	2.05e-05	4.85e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CREBBP—esophageal cancer	2.05e-05	4.85e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NOS3—esophageal cancer	2.02e-05	4.76e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—esophageal cancer	1.84e-05	4.36e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NOS3—esophageal cancer	1.84e-05	4.34e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—EP300—esophageal cancer	1.71e-05	4.04e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—esophageal cancer	1.68e-05	3.97e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—EP300—esophageal cancer	1.53e-05	3.62e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—EP300—esophageal cancer	1.4e-05	3.3e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—esophageal cancer	1.26e-05	2.99e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—esophageal cancer	1.13e-05	2.68e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.03e-05	2.44e-05	CbGpPWpGaD
